Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Sep;33(9):583-90.
doi: 10.1002/clc.20804.

Comparison of sirolimus- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Yong-le Li  1 , Zheng Wan, Wen-li Lu, Jian-hua Wang
Affiliations
Meta-Analysis

Comparison of sirolimus- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Yong-le Li et al. Clin Cardiol. 2010 Sep.

Abstract

Background: It has been reported that sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) have been more effective than bare-metal stents in reducing restenosis and cardiac events in a broad range of patients with coronary artery disease. However, it is unknown whether there might be differences between these two drug-eluting stents in terms of efficacy and safety in the setting of acute ST-segment elevation myocardial infarction (STEMI).

Hypothesis: The aim of the present study was to compare SES with PES in patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI).

Methods: The published research was scanned by formal searches of electronic databases (PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials) from January 2001 to February 2010. Internet-based sources of information on the results of clinical trials in cardiology were also searched.

Results: A total of 4 randomized trials were included in the present meta-analysis, involving 1105 patients (550 in the SES group, 555 in the PES group). SES were significantly more effective in the reduction of angiographic binary (≥50%) restenosis (4.0% vs 9.6%, odds ratio 0.38, 95% confidence interval 0.19 to 0.74, P = 0.004) compared to PES. The differences between SES and PES were not statistically significant with respect to target vessel revascularization (TVR), stent thrombosis, cardiac death, and myocardial infarction.

Conclusions: SES are superior to PES in reducing the incidence of restenosis in patients undergoing primary PCI for STEMI, with nonsignificant differences in terms of TVR, cardiac death, myocardial infarction, and stent thrombosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Odds ratios of target vessel revascularization associated with sirolimus‐eluting stents (SES) vs paclitaxel‐eluting stents (PES) in patients with acute ST‐segment elevation myocardial infarction. Abbreviations: CI, confidence interval.
Figure 2
Figure 2
Odds ratios of angiographic restenosis associated with sirolimus‐eluting stents (SES) vs paclitaxel‐eluting stents (PES) in patients with acute ST‐segment elevation myocardial infarction. Abbreviations: CI, confidence interval.
Figure 3
Figure 3
Odds ratios of stent thrombosis associated with sirolimus‐eluting stents (SES) vs paclitaxel‐eluting stents (PES) in patients with acute ST‐segment elevation myocardial infarction. Abbreviations: CI, confidence interval.
See this image and copyright information in PMC

References

    1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20. - PubMed
    1. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta‐analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297–301. - PubMed
    1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–1323. - PubMed
    1. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimuseluting stents with bare‐metal stents. N Engl J Med 2007; 356: 1030–1039. - PubMed
    1. Melfi R, Nusca A, Patti G, et al. The risks and benefits of drug‐eluting stents in the setting of STEMI. Curr Cardiol Rep 2008; 10: 402–406. - PubMed